Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Dissecting the cancer epigenome – fundamental lessons from developmental biology

Project description

Exploring the epigenetics of unique genome regulation mechanisms

DNA methylation plays a key role in controlling gene expression and is essential for normal development and functioning of cells. This mechanism is often significantly altered in malignant cancers. Funded by the European Research Council, the CancerEpigenome project suggests that these alterations closely mirror patterns that emerge in the early placenta. Researchers deem that both the cancer and the placental epigenome reflect a switch-like programming event that can be triggered without genetic mutation. To prove this and investigate this unique form of genome regulation, researchers will use innovative in vivo and in vitro platforms. Project findings could help resolve long-standing paradoxes in epigenetics research and provide a complete model of epigenetic transformation with direct disease implications.

Objective

DNA methylation is a tightly controlled mechanism that is essential for normal development and genome regulation. Although maintained in a highly static pattern across healthy tissues, DNA methylation is globally reprogrammed in nearly all malignant cancers, including gains at thousands of gene promoters and global loss across large domains. Substantial work from our group to characterize multiple primary tumor cohorts, transgenic animal models, and cancer cell lines finds that current experimental systems rarely, if ever, capture key features of the cancer epigenome. In contrast, our parallel efforts to understand epigenetic dynamics in development suggest an alternative, highly innovative hypothesis with a clear path for investigation. We find that the epigenetic alterations in cancer very closely mirror patterns that emerge in the early placenta, a tissue that naturally acquires invasive, immune suppressive, angiogenic, metabolically plastic and mutationally tolerant properties. Notably, this cancer-like epigenome depends on dynamic, previously undiscovered configurations of regulators that can be triggered without genetic mutation. With these insights, we have innovated tractable in vitro and in vivo platforms to dissect the biochemical, genetic, and physiological properties of this unique form of genome regulation as it supports developmental processes. We believe these efforts will demonstrate that the placenta and by extrapolation the cancer epigenome reflect a switch-like reprogramming event that can be studied at high resolution. In line with the ERC-ADG program’s goals, we will pursue ambitious and critical questions, resolve long-standing paradoxes and provide a complete model of epigenetic transformation in development with direct disease implications. Our world-class interdisciplinary team, extensive preliminary data, experimental design and proven track-record will enable us to turn this grant into high-impact and translationally relevant discoveries.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-ADG

See all projects funded under this call

Host institution

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Net EU contribution
€ 2 487 500,00
Address
HOFGARTENSTRASSE 8
80539 MUNCHEN
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
€ 2 487 500,00

Beneficiaries (1)